Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sectors.

Mr. Cable currently serves as Vice Chairman of Goodwin and as Global Chair of M&A. Mr. Cable previously served as Chair of the firm’s Corporate Department, as Chair of its Hiring Committee, as Chair of its Incubator Program, and as a member of the firm's Executive and Allocations Committees.

Areas of Practice
Domaines D’Expertise





Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. He represents buyers, sellers and investment banks in his M&A practice, as well as the private equity and venture sources investing in such companies and investment banks serving such industries. 

During his distinguished career, Mr. Cable has played a central role in executing more than 400 M&A transactions, with a particular focus on the technology and life sciences industries. In addition to his M&A work, Mr. Cable regularly represents issuers and underwriters in a myriad of capital market offerings. 

Mr. Cable’s representative clients include, among others: AMAG, Ansys, AvroBio, Aura, Cerevel, Citrix, Corbus, Flagship Pioneering, Mirati, Moderna, MyoKardia, Ohana, PAREXEL, PTC, Repertoire Immune Medicines, Plug Power, Rubius, Shields Healthcare Solutions, Spark, Valo Health, and Yumanity.

Representative Transactions

His recent and notable representations include: 

  • Financial advisor in connection with Pandion Therapeutics’ 2021 definitive sale to Merck ($1.85 billion)
  • The Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio
  • MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
  • AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
  • Macquarie Capital and GCM Grosvenor in connection with their 2020 agreement to acquire Alaska Communications Systems Group ($500 million)
  • Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp II ($440 million)
  • Financial advisor in connection with Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion) 
  • Moderna in its 2020 follow-on public offerings ($500 million in March and $1.34 billion in May)
  • The Transaction Committee of Sprint in connection with Sprint Corporation’s 2020 merger with T-Mobile US, Inc. ($26 billion)
  • Financial advisor in connection with Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion) 
  • Financial advisor in connection with Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
  • Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
  • Financial advisor in connection with Arqule’s 2020 acquisition by Merck ($2.7 billion)
  • Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
  • Moderna in its 2018 record initial public offering ($604 million) 
  • Keryx in its 2018 merger with Akebia ($1.3 billion)
  • PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
  • Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
  • The private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals
  • The abandoned 2018 acquisition of NXP by Qualcomm ($47 billion)
  • inviCRO in its 2017 sale to Konica Minolta (Japan) ($300 million)
  • PAREXEL in its 2017 sale to Pamplona ($5 billion)
  • AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
  • Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
  • Financial advisor in connection with Pharmacyclics’ 2015 sale to AbbVie ($21 billion)
  • AMRI in its 2016 and 2015 cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain)
  • The private company sale of Stemcentrix to Abbvie ($5.8 billion)
  • The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion) 
  • Xoom in its 2015 sale to PayPal ($1 billion)
  • Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion) 
  • Eloqua in its 2012 sale to Oracle ($1 billion)

Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio and the Transaction Committee of Sprint in Sprint Corporation’s merger with T-Mobile US, Inc.


Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.

A Life Sciences pioneer, Mr. Cable founded Goodwin Labs in February 2020, a groundbreaking new program supporting startups and emerging life sciences companies as well as the overall life sciences ecosystem through innovative legal, strategic and educational services. The focus of Goodwin Labs is giving back to the life sciences community and creating opportunities for junior lawyers to interact with emerging companies.

In 2006, Mr. Cable founded Goodwin's Directors Forum, the firm's annual continuing education program designed specifically for the independent directors of the firm’s public company clients. This interactive and hands-on nature of the discussions has been a core feature of the Directors Forum since its first run 14 years ago. In the many years we have been advising public company boards, we have found there is no substitute for shared experiences.

Mr. Cable leads the firm’s pro bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors. Mr. Cable is also a member of the Goodwin pro bono team advising the Boston Red Sox Foundation on Board and governance matters.


Mr. Cable is continually recognized for his leadership in the life sciences industry on both the U.S. domestic and global levels, and has been included in numerous legal guides for his expertise.

  • Most recently, Mr. Cable was recognized in Corporate/M&A (International & Cross-Border) by Chambers Global 2021
  • Recently, Mr. Cable was named a fellow in the American College of Governance Counsel, a professional, educational, and honorary association of lawyers widely-recognized for their achievements in the field of governance
  • In 2019, he was recognized by LMG Life Sciences as Corporate Attorney of the Year
  • In 2017, Mr. Cable was recognized by Law360 as Life Sciences MVP
  • In 2016, Mr. Cable was recognized by LMG Life Sciences as Life Sciences Transaction Attorney of the Year
  • Mr. Cable also was recognized by the Financial Times winning its award in 2015 for Innovative Deal of the Year in advising Foundation Medicine in its $1 billion majority purchase by Roche, and in 2016 advising Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn
  • Global M&A Network has named Mr. Cable one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year
  • Mr. Cable is annually ranked in:
    • Chambers USA (Corporate/M&A: Massachusetts – Band 1)
    • Chambers Global (Corporate M&A: International & Cross-Border – USA – Band 4)
    • America’s Leading Lawyers for Business (Corporate/M&A – Band 1)
    • U.S. News-Best Lawyers (Corporate Law)
    • The Legal 500 (Leading Lawyer: M&A/Corporate & Commercial – Middle Market)

In The News









J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)

Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique